Skip to main content
Top
Published in: Critical Care 6/2012

Open Access 01-12-2012 | Research

Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality

Authors: Ana Díaz-Martín, María Luisa Martínez-González, Ricard Ferrer, Carlos Ortiz-Leyba, Enrique Piacentini, Maria Jesus Lopez-Pueyo, Ignacio Martín-Loeches, Mitchell M Levy, Antoni Artigas, José Garnacho-Montero, for the Edusepsis Study Group

Published in: Critical Care | Issue 6/2012

Login to get access

Abstract

Introduction

Although early institution of adequate antimicrobial therapy is lifesaving in sepsis patients, optimal antimicrobial strategy has not been established. Moreover, the benefit of combination therapy over monotherapy remains to be determined. Our aims are to describe patterns of empiric antimicrobial therapy in severe sepsis, assessing the impact of combination therapy, including antimicrobials with different mechanisms of action, on mortality.

Methods

This is a Spanish national multicenter study, analyzing all patients admitted to ICUs who received antibiotics within the first 6 hours of diagnosis of severe sepsis or septic shock. Antibiotic-prescription patterns in community-acquired infections and nosocomial infections were analyzed separately and compared. We compared the impact on mortality of empiric antibiotic treatment, including antibiotics with different mechanisms of action, termed different-class combination therapy (DCCT), with that of monotherapy and any other combination therapy possibilities (non-DCCT).

Results

We included 1,372 patients, 1,022 (74.5%) of whom had community-acquired sepsis and 350 (25.5%) of whom had nosocomial sepsis. The most frequently prescribed antibiotic agents were β-lactams (902, 65.7%) and carbapenems (345, 25.1%). DCCT was administered to 388 patients (28.3%), whereas non-DCCT was administered to 984 (71.7%). The mortality rate was significantly lower in patients administered DCCTs than in those who were administered non-DCCTs (34% versus 40%; P = 0.042). The variables independently associated with mortality were age, male sex, APACHE II score, and community origin of the infection. DCCT was a protective factor against in-hospital mortality (odds ratio (OR), 0.699; 95% confidence interval (CI), 0.522 to 0.936; P = 0.016), as was urologic focus of infection (OR, 0.241; 95% CI, 0.102 to 0.569; P = 0.001).

Conclusions

β-Lactams, including carbapenems, are the most frequently prescribed antibiotics in empiric therapy in patients with severe sepsis and septic shock. Administering a combination of antimicrobials with different mechanisms of action is associated with decreased mortality.
Literature
1.
go back to reference Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002CrossRefPubMed Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002CrossRefPubMed
2.
go back to reference Esteban A, Frutos-Vivar F, Ferguson ND, Penuelas O, Lorente JA, Gordo F, Honrubia T, Algora A, Bustos A, Garcia G, Díaz-Regañón IR, de Luna RR: Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med 2007, 35: 1284-1289. 10.1097/01.CCM.0000260960.94300.DECrossRefPubMed Esteban A, Frutos-Vivar F, Ferguson ND, Penuelas O, Lorente JA, Gordo F, Honrubia T, Algora A, Bustos A, Garcia G, Díaz-Regañón IR, de Luna RR: Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med 2007, 35: 1284-1289. 10.1097/01.CCM.0000260960.94300.DECrossRefPubMed
3.
go back to reference Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulme R, Lepage E, Le Gall R: Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002, 28: 108-121. 10.1007/s00134-001-1143-zCrossRefPubMed Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulme R, Lepage E, Le Gall R: Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002, 28: 108-121. 10.1007/s00134-001-1143-zCrossRefPubMed
4.
go back to reference Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Perez XL, Sirvent JM: Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009, 180: 861-866. 10.1164/rccm.200812-1912OCCrossRefPubMed Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Perez XL, Sirvent JM: Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009, 180: 861-866. 10.1164/rccm.200812-1912OCCrossRefPubMed
5.
go back to reference Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31: 2742-2751. 10.1097/01.CCM.0000098031.24329.10CrossRefPubMed Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31: 2742-2751. 10.1097/01.CCM.0000098031.24329.10CrossRefPubMed
6.
go back to reference Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34: 17-60. 10.1007/s00134-007-0934-2PubMedCentralCrossRefPubMed Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34: 17-60. 10.1007/s00134-007-0934-2PubMedCentralCrossRefPubMed
7.
go back to reference Al-Hasan MN, Wilson JW, Lahr BD, Thomsen KM, Eckel-Passow JE, Vetter EA, Tleyjeh IM, Baddour LM: Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli. Antimicrob Agents Chemother 2009, 53: 1386-1394. 10.1128/AAC.01231-08PubMedCentralCrossRefPubMed Al-Hasan MN, Wilson JW, Lahr BD, Thomsen KM, Eckel-Passow JE, Vetter EA, Tleyjeh IM, Baddour LM: Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli. Antimicrob Agents Chemother 2009, 53: 1386-1394. 10.1128/AAC.01231-08PubMedCentralCrossRefPubMed
8.
go back to reference Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J: Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007, 35: 1888-1895. 10.1097/01.CCM.0000275389.31974.22CrossRefPubMed Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J: Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007, 35: 1888-1895. 10.1097/01.CCM.0000275389.31974.22CrossRefPubMed
9.
go back to reference Weiss K, Tillotson GS: The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest 2005, 128: 940-946. 10.1378/chest.128.2.940CrossRefPubMed Weiss K, Tillotson GS: The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest 2005, 128: 940-946. 10.1378/chest.128.2.940CrossRefPubMed
10.
go back to reference Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y, Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S: Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38: 1773-1785. 10.1097/CCM.0b013e3181eb3ccdCrossRefPubMed Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y, Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S: Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38: 1773-1785. 10.1097/CCM.0b013e3181eb3ccdCrossRefPubMed
11.
go back to reference Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garnacho-Montero J, Ibanez J, Palencia E, Quintana M, de la Torre-Prados MV: Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008, 299: 2294-2303. 10.1001/jama.299.19.2294CrossRefPubMed Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garnacho-Montero J, Ibanez J, Palencia E, Quintana M, de la Torre-Prados MV: Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008, 299: 2294-2303. 10.1001/jama.299.19.2294CrossRefPubMed
12.
go back to reference Suarez D, Ferrer R, Artigas A, Azkarate I, Garnacho-Montero J, Goma G, Levy MM, Ruiz JC: Cost-effectiveness of the Surviving Sepsis Campaign protocol for severe sepsis: a prospective nation-wide study in Spain. Intensive Care Med 2011, 37: 444-452. 10.1007/s00134-010-2102-3CrossRefPubMed Suarez D, Ferrer R, Artigas A, Azkarate I, Garnacho-Montero J, Goma G, Levy MM, Ruiz JC: Cost-effectiveness of the Surviving Sepsis Campaign protocol for severe sepsis: a prospective nation-wide study in Spain. Intensive Care Med 2011, 37: 444-452. 10.1007/s00134-010-2102-3CrossRefPubMed
13.
go back to reference Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, Sirio CA, Murphy DJ, Lotring T, Damiano A, Harrell FE: The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991, 100: 1619-1636. 10.1378/chest.100.6.1619CrossRefPubMed Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, Sirio CA, Murphy DJ, Lotring T, Damiano A, Harrell FE: The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991, 100: 1619-1636. 10.1378/chest.100.6.1619CrossRefPubMed
14.
go back to reference Angel Diaz M, Ramon Hernandez J, Martinez-Martinez L, Rodriguez-Bano J, Pascual A: [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)]. Enferm Infecc Microbiol Clin 2009, 27: 503-510. 10.1016/j.eimc.2008.09.006CrossRefPubMed Angel Diaz M, Ramon Hernandez J, Martinez-Martinez L, Rodriguez-Bano J, Pascual A: [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)]. Enferm Infecc Microbiol Clin 2009, 27: 503-510. 10.1016/j.eimc.2008.09.006CrossRefPubMed
15.
go back to reference Kock R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, Mielke M, Peters G, Skov RL, Struelens MJ, Tacconelli E, Navarro Torné A, Witte W, Friedrich AW: Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010, 15: 19688.PubMed Kock R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, Mielke M, Peters G, Skov RL, Struelens MJ, Tacconelli E, Navarro Torné A, Witte W, Friedrich AW: Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010, 15: 19688.PubMed
16.
go back to reference Kumar A: Optimizing antimicrobial therapy in sepsis and septic shock. Crit Care Clin 2009, 25: 733-751. viii 10.1016/j.ccc.2009.08.004CrossRefPubMed Kumar A: Optimizing antimicrobial therapy in sepsis and septic shock. Crit Care Clin 2009, 25: 733-751. viii 10.1016/j.ccc.2009.08.004CrossRefPubMed
17.
go back to reference de With K, Meyer E, Steib-Bauert M, Schwab F, Daschner FD, Kern WV: Antibiotic use in two cohorts of German intensive care units. J Hosp Infect 2006, 64: 231-237. 10.1016/j.jhin.2006.05.018CrossRefPubMed de With K, Meyer E, Steib-Bauert M, Schwab F, Daschner FD, Kern WV: Antibiotic use in two cohorts of German intensive care units. J Hosp Infect 2006, 64: 231-237. 10.1016/j.jhin.2006.05.018CrossRefPubMed
18.
go back to reference Rodriguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Sole-Violan J, Rello J: Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35: 1493-1498. 10.1097/01.CCM.0000266755.75844.05CrossRefPubMed Rodriguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Sole-Violan J, Rello J: Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35: 1493-1498. 10.1097/01.CCM.0000266755.75844.05CrossRefPubMed
19.
go back to reference Rotschafer JC, Ullman MA, Sullivan CJ: Optimal use of fluoroquinolones in the intensive care unit setting. Crit Care Clin 2011, 27: 95-106. 10.1016/j.ccc.2010.11.005CrossRefPubMed Rotschafer JC, Ullman MA, Sullivan CJ: Optimal use of fluoroquinolones in the intensive care unit setting. Crit Care Clin 2011, 27: 95-106. 10.1016/j.ccc.2010.11.005CrossRefPubMed
20.
go back to reference Dupont H, Carbon C, Carlet J: Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial: The Severe Generalized Peritonitis Study Group. Antimicrob Agents Chemother 2000, 44: 2028-2033. 10.1128/AAC.44.8.2028-2033.2000PubMedCentralCrossRefPubMed Dupont H, Carbon C, Carlet J: Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial: The Severe Generalized Peritonitis Study Group. Antimicrob Agents Chemother 2000, 44: 2028-2033. 10.1128/AAC.44.8.2028-2033.2000PubMedCentralCrossRefPubMed
21.
go back to reference Damas P, Garweg C, Monchi M, Nys M, Canivet JL, Ledoux D, Preiser JC: Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779]. Crit Care 2006, 10: R52. 10.1186/cc4879PubMedCentralCrossRefPubMed Damas P, Garweg C, Monchi M, Nys M, Canivet JL, Ledoux D, Preiser JC: Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779]. Crit Care 2006, 10: R52. 10.1186/cc4879PubMedCentralCrossRefPubMed
22.
go back to reference Heyland DK, Dodek P, Muscedere J, Day A, Cook D: Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008, 36: 737-744. 10.1097/01.CCM.0B013E31816203D6CrossRefPubMed Heyland DK, Dodek P, Muscedere J, Day A, Cook D: Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008, 36: 737-744. 10.1097/01.CCM.0B013E31816203D6CrossRefPubMed
23.
go back to reference Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170: 440-444. 10.1164/rccm.200311-1578OCCrossRefPubMed Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170: 440-444. 10.1164/rccm.200311-1578OCCrossRefPubMed
24.
go back to reference Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP: Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007, 51: 3977-3982. 10.1128/AAC.00006-07PubMedCentralCrossRefPubMed Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP: Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007, 51: 3977-3982. 10.1128/AAC.00006-07PubMedCentralCrossRefPubMed
25.
go back to reference Tessmer A, Welte T, Martus P, Schnoor M, Marre R, Suttorp N: Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother 2009, 63: 1025-1033. 10.1093/jac/dkp088CrossRefPubMed Tessmer A, Welte T, Martus P, Schnoor M, Marre R, Suttorp N: Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother 2009, 63: 1025-1033. 10.1093/jac/dkp088CrossRefPubMed
26.
go back to reference Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004, 328: 668. 10.1136/bmj.38028.520995.63PubMedCentralCrossRefPubMed Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004, 328: 668. 10.1136/bmj.38028.520995.63PubMedCentralCrossRefPubMed
27.
go back to reference Safdar N, Handelsman J, Maki DG: Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004, 4: 519-527. 10.1016/S1473-3099(04)01108-9CrossRefPubMed Safdar N, Handelsman J, Maki DG: Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004, 4: 519-527. 10.1016/S1473-3099(04)01108-9CrossRefPubMed
28.
go back to reference Kumar A, Safdar N, Kethireddy S, Chateau D: A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010, 38: 1651-1664. 10.1097/CCM.0b013e3181e96b91CrossRefPubMed Kumar A, Safdar N, Kethireddy S, Chateau D: A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010, 38: 1651-1664. 10.1097/CCM.0b013e3181e96b91CrossRefPubMed
29.
go back to reference Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, Plachouras D, Kollias S, Raftogiannis M, Zervakis D, Baziaka F, Koronaios A, Antonopoulou A, Markaki V, Koutoukas P, Papadomichelakis E, Tsaganos T, Armaganidis A, Koussoulas V, Kotanidou A, Roussos C, Giamarellou H: Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008, 46: 1157-1164. 10.1086/529439CrossRefPubMed Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, Plachouras D, Kollias S, Raftogiannis M, Zervakis D, Baziaka F, Koronaios A, Antonopoulou A, Markaki V, Koutoukas P, Papadomichelakis E, Tsaganos T, Armaganidis A, Koussoulas V, Kotanidou A, Roussos C, Giamarellou H: Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008, 46: 1157-1164. 10.1086/529439CrossRefPubMed
30.
go back to reference Metersky ML, Ma A, Houck PM, Bratzler DW: Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007, 131: 466-473. 10.1378/chest.06-1426CrossRefPubMed Metersky ML, Ma A, Houck PM, Bratzler DW: Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007, 131: 466-473. 10.1378/chest.06-1426CrossRefPubMed
31.
go back to reference Parnham MJ: Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005, 18: 125-131. 10.1097/01.qco.0000160901.71813.feCrossRefPubMed Parnham MJ: Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005, 18: 125-131. 10.1097/01.qco.0000160901.71813.feCrossRefPubMed
32.
go back to reference Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115: 529-535. 10.1016/j.amjmed.2003.07.005CrossRefPubMed Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115: 529-535. 10.1016/j.amjmed.2003.07.005CrossRefPubMed
Metadata
Title
Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality
Authors
Ana Díaz-Martín
María Luisa Martínez-González
Ricard Ferrer
Carlos Ortiz-Leyba
Enrique Piacentini
Maria Jesus Lopez-Pueyo
Ignacio Martín-Loeches
Mitchell M Levy
Antoni Artigas
José Garnacho-Montero
for the Edusepsis Study Group
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Critical Care / Issue 6/2012
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc11869

Other articles of this Issue 6/2012

Critical Care 6/2012 Go to the issue